Overview A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas. Phase: Phase 1 Details Lead Sponsor: Reata Pharmaceuticals, Inc.